1. Introduction {#sec1}
===============

Papillary thyroid carcinoma (PTC) is the most common form of thyroid malignancy with a good prognosis, since it is generally confined to the neck with or without spread to regional lymph nodes \[[@B1]\]. However, distant metastases are rare and mainly include lung and bone \[[@B2]\]. Metastasis affecting oral and maxillofacial region is extremely rare, occurring in 0.2‰ of all cases of thyroid carcinoma \[[@B3]\]. We report the first case of a malar metastasis revealing a follicular variant of papillary thyroid carcinoma (FVPTC).

2. Case Report {#sec2}
==============

In November 2008, a 67-years-old female was referred to our hospital with the complaint of a slow-growing painless swelling of 6 months duration on her left cheek. She had a medical history of left lobo-isthmectomy of the thyroid gland, seven years ago, with unspecified histology.

Physical examination showed a 5 × 5 cm, firm, and immobile mass of the left malar area without significant lymphadenopathy. The neurological examination and visual acuity were normal.

A computed tomography (CT) scan showed a 6.0 × 5.5 × 4.5 cm hypervascular soft tissue mass within the left malar region with bony destruction and extension to the lateral walls of the maxilla and the orbit ([Figure 1](#fig1){ref-type="fig"}).

An incisional biopsy was performed. The histopathological examination was very suggestive of acinar cell carcinoma of salivary glands. Taking into account her history of thyroid pathology and the absence of a salivary mass, a rereading of the biopsy slides with immunohistochemical studies showed expression of thyroglobulin (Tg) by the tumor cells and confirmed zygomatic bone metastasis of a PTC.

The thyroid ultrasonography revealed an increased right lobe with a 1.6 cm hypoecogenic nodule. Surgical resection was scheduled. Preoperative chest radiographs and subsequent CT showed lung metastases. In February 2009, the patient underwent surgical resection of the malar mass and a simultaneous completion thyroidectomy with central lymph node dissection. Histopathology confirmed the diagnosis of 3 foci of papillary thyroid microcarcinoma in his follicular variant ([Figure 2](#fig2){ref-type="fig"}), with metastasis to the malar bone ([Figure 3](#fig3){ref-type="fig"}) (TNM classification \[6th ed.\]: pT1m N1a M1).

The patient was then referred to our department for postoperative radioiodine (I131) therapy. She received 5.55 GBq (150 mCi) of I131 after 3 weeks of L-thyroxin withdrawal. Planar total body scintigraphy was performed after 4 days with a mono-head gamma camera (Siemens Integrated Orbiter) showing radioiodine-avid foci in the left cheek region, thyroid bed, and lungs. The TSH-stimulated serum Tg level was 175 ng/mL (absence of anti-Tg antibodies). Six months later, new serum measurement reveals a decreasing of the Tg level (on TSH stimulation) to 18 ng/mL. Patient was given a second high-dose radioiodine therapy (5.55 GBq). Postablative I131 whole-body scan was performed, followed by SPECT/CT scan of the neck and chest, to correlate functional and anatomical images, with a Symbia T camera ([Figure 4](#fig4){ref-type="fig"}). Fused images showed a complete attenuation of tracer uptake on the neck and the facial region, except for a focus on the left orbit, with unchanged appearance of the micronodular pulmonary metastases. Being avid to I131, the patient was given two other therapeutic radioiodine cures (2 × 5.55 GBq). The follow-up dignostic I131 scan (March 2012) was negative with undetectable TSH-stimulated thyroglobulin (absence of anti-Tg antibodies). The patient was considered in remission and will be followed by cervical ultrasound, Tg, and diagnostic whole-body I131 scans, on the basis of the department\'s protocol.

3. Discussion {#sec3}
=============

Approximately 90% of malignant thyroid tumors well differentiated and are classified as PTC (80%) or follicular carcinoma (10%) \[[@B1]\]. The Follicular variant of papillary thyroid carcinoma is a major subtype of PTC \[[@B4]\]. Patients with FVPTC and patients with classical PTC showed similar clinical characteristics and prognostic factors. Survival was comparable in both groups \[[@B5]\]. A minority of patients may present, or subsequently develop, locoregional and distant metastases that may adversely affect survival \[[@B6]\]. Distant metastases occur in 4% to 8% of patients with PTC \[[@B4]--[@B7]\]. Bone metastasis is the second most common metastatic site after lung. Follicular thyroid carcinoma is known to metastasize via the bloodstream; such a pattern of spread is rare in papillary thyroid carcinoma \[[@B8]\]. The latter exhibits more propensities for lymphatic spread. There have been a few reports of "aggressive" FVPTC that have metastasized hematogenously; these neoplasms have been diffusely invasive or multicentric in the thyroid \[[@B9]\].

Metastatic thyroid carcinoma rarely involves the oral and maxillofacial (OMF) region. They constitute 5.8% of all OMF metastasis, and they are usually located in the jaw bones \[[@B3]\].

According to the literature, the zygomatic bone is a very unusual site for metastasis. We found only 5 cases of metastatic localization from lung, rectum, liver, uterine and breast cancer \[[@B10]--[@B14]\]. To our knowledge, this is the first recorded instance of a malar metastasis from FVPTC.

The optimal treatment of such cases may be a simultaneous resection of the solitary bony metastases along with total thyroidectomy followed by radioiodine therapy with subsequent adequate radiotherapy. This may provide a better prognosis because of the enhanced uptake and increased effectiveness of postoperative radioiodine in dealing with other systemic micrometastases that are otherwise undetectable \[[@B2], [@B8]\].

Common malignancies can metastasize to unusual sites and, although infrequent, may be the presenting feature. Although uncommon, OMF lesions can be the first manifestation of a differentiated thyroid carcinoma. This is the first report of a FVPTC presenting as a malar metastasis. The successful management of such cases may be achieved by a multidisciplinary approach.

![CT of the face with contrast that showed a large enhancing soft tissue mass involving the left malar bone with maxillary wall extension.](CRIM.OTOLARYNGOLOGY2012-795686.001){#fig1}

![Histologic section of the remaining lobe showing a papillary carcinomatous nodule surrounded by lymphocytic thyroiditis lesions (H&E; original magnification-40x).](CRIM.OTOLARYNGOLOGY2012-795686.002){#fig2}

![Papillary carcinoma invading the malar bone (H&E; original magnification-20x).](CRIM.OTOLARYNGOLOGY2012-795686.003){#fig3}

![The second post-therapeutic I131 whole-body scan ((a) anterior view; (b) posterior view) showed a regression of the neck foci, an attenuation of the facial uptake, and a stability of lung metastases. SPECT/CT fusion images ((c) and (d): left, SPECT; middle, CT; right, SPECT/CT) established that facial focus corresponded to a remaining circumscribed metastasis of the lateral wall of the left orbit. Coronal SPECT/CT image fusion (d) confirmed micronodular pulmonary metastases.](CRIM.OTOLARYNGOLOGY2012-795686.004){#fig4}
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